Beatrice Biferali
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Beatrice Biferali has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Chiara Mozzetta
IRCCS Fondazione Santa Lucia, Rome, Italy
2 shared publications - Daniele Campolungo
Gene Expression Regulation Unit, Division of Genetics and Cell Biology, IRCCS Ospedale San Raffaele, Milan, Italy
2 shared publications - Davide Gabellini
Gene Expression Regulation Unit, Division of Genetics and Cell Biology, IRCCS Ospedale San Raffaele, Milan, Italy
2 shared publications - Mara Salomè
Paul O’Gorman Leukaemia Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK
2 shared publications Alessio Colantoni
Department of Biology and Biotechnology Charles Darwin, Sapienza University of Rome, Rome, Italy
1 shared publication- Andrea Cipriano
Department of Genetics and Stanford University School of Medicine, Stanford University, Stanford, USA
1 shared publication
Latest Publications
- 20 November 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (47)
The interferon-gamma response pathway is a targetable driver of FSHD muscular dystrophy progression
Facioscapulohumeral muscular dystrophy (FSHD) is a leading neuromuscular disorder caused by the aberrant expression of the transcription factor double homeobox 4 (DUX4) in skeletal muscle. While DUX4 is normally restricted to early embryonic development, its reactivation in FSHD triggers chronic inflammation and progressive muscle degeneration. However, the precise molecular links between DUX4 and persistent immune activation remain poorly understood. Here, we show that DUX4 induces a viral mimicry-like pathway that is fundamentally uncoupled from canonical type I interferon (IFN) activation. Instead, DUX4 establishes a non-canonical innate immune state dominated by IFN-γ signaling, providing a mechanistic explanation for the non-resolving inflammation characteristic of the disease. We demonstrate that while IFN-γ treatment alone is sufficient to recapitulate key DUX4 pathogenic effects, its inhibition rescues muscle inflammation and halts disease progression in FSHD models. These findings define a “skewed viral mimicry” process driven by a disease-specific transcription factor and identify IFN-γ as a primary therapeutic target for tissue-informed immunomodulation in muscular dystrophy.
- 20 November 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (47)
The interferon-gamma response pathway is a targetable driver of FSHD muscular dystrophy progression
Facioscapulohumeral muscular dystrophy (FSHD) is a leading neuromuscular disorder caused by the aberrant expression of the transcription factor double homeobox 4 (DUX4) in skeletal muscle. While DUX4 is normally restricted to early embryonic development, its reactivation in FSHD triggers chronic inflammation and progressive muscle degeneration. However, the precise molecular links between DUX4 and persistent immune activation remain poorly understood. Here, we show that DUX4 induces a viral mimicry-like pathway that is fundamentally uncoupled from canonical type I interferon (IFN) activation. Instead, DUX4 establishes a non-canonical innate immune state dominated by IFN-γ signaling, providing a mechanistic explanation for the non-resolving inflammation characteristic of the disease. We demonstrate that while IFN-γ treatment alone is sufficient to recapitulate key DUX4 pathogenic effects, its inhibition rescues muscle inflammation and halts disease progression in FSHD models. These findings define a “skewed viral mimicry” process driven by a disease-specific transcription factor and identify IFN-γ as a primary therapeutic target for tissue-informed immunomodulation in muscular dystrophy.
- Open Access
- 15 September 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (37) , eadi3771
DUX4-r exerts a neomorphic activity that depends on GTF2I in acute lymphoblastic leukemia
Translocations producing rearranged versions of the transcription factor double homeobox 4 (DUX4-r) are one of the most frequent causes of B cell acute lymphoblastic leukemia (B-ALL). DUX4-r retains the DNA binding domain of wild-type DUX4 but is truncated on the C-terminal transcription activation domain. The precise mechanism through which DUX4-r causes leukemia is unknown, and no targeted therapy is currently available. We found that the rearrangement leads to both a loss and a gain of function in DUX4-r. Loss of CBP/EP300 transcriptional coactivator interaction leads to an inability to bind and activate repressed chromatin. Concurrently, a gain of interaction with the general transcription factor 2 I (GTF2I) redirects DUX4-r toward leukemogenic targets. This neomorphic activity exposes an Achilles’ heel whereby DUX4-r–positive leukemia cells are exquisitely sensitive to GTF2I targeting, which inhibits DUX4-r leukemogenic activity. Our work elucidates the molecular mechanism through which DUX4-r causes leukemia and suggests a possible therapeutic avenue tailored to this B-ALL subtype.
- 15 September 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (37) , eadi3771
Open AccessDUX4-r exerts a neomorphic activity that depends on GTF2I in acute lymphoblastic leukemia
Translocations producing rearranged versions of the transcription factor double homeobox 4 (DUX4-r) are one of the most frequent causes of B cell acute lymphoblastic leukemia (B-ALL). DUX4-r retains the DNA binding domain of wild-type DUX4 but is truncated on the C-terminal transcription activation domain. The precise mechanism through which DUX4-r causes leukemia is unknown, and no targeted therapy is currently available. We found that the rearrangement leads to both a loss and a gain of function in DUX4-r. Loss of CBP/EP300 transcriptional coactivator interaction leads to an inability to bind and activate repressed chromatin. Concurrently, a gain of interaction with the general transcription factor 2 I (GTF2I) redirects DUX4-r toward leukemogenic targets. This neomorphic activity exposes an Achilles’ heel whereby DUX4-r–positive leukemia cells are exquisitely sensitive to GTF2I targeting, which inhibits DUX4-r leukemogenic activity. Our work elucidates the molecular mechanism through which DUX4-r causes leukemia and suggests a possible therapeutic avenue tailored to this B-ALL subtype.
- Open Access
- 4 June 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 7 (23) , eabd9371
Prdm16-mediated H3K9 methylation controls fibro-adipogenic progenitors identity during skeletal muscle repair
A druggable mechanism is found to reprogram fibro-adipogenic progenitors toward myogenesis and to improve muscle repair.
- 4 June 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 7 (23) , eabd9371
Open AccessPrdm16-mediated H3K9 methylation controls fibro-adipogenic progenitors identity during skeletal muscle repair
A druggable mechanism is found to reprogram fibro-adipogenic progenitors toward myogenesis and to improve muscle repair.
- Open Access
- 12 January 2021
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 10
Epigenetic regulation of Wnt7b expression by the cis-acting long noncoding RNA Lnc-Rewind in muscle stem cells
Skeletal muscle possesses an outstanding capacity to regenerate upon injury due to the adult muscle stem cell (MuSC) activity. This ability requires the proper balance between MuSC expansion and differentiation, which is critical for muscle homeostasis and contributes, if deregulated, to muscle diseases. Here, we functionally characterize a novel chromatin-associated long noncoding RNA (lncRNA), Lnc-Rewind, which is expressed in murine MuSCs and conserved in human. We find that, in mouse, Lnc-Rewind acts as an epigenetic regulator of MuSC proliferation and expansion by influencing the expression of skeletal muscle genes and several components of the WNT (Wingless-INT) signalling pathway. Among them, we identified the nearby Wnt7b gene as a direct Lnc-Rewind target. We show that Lnc-Rewind interacts with the G9a histone lysine methyltransferase and mediates the in cis repression of Wnt7b by H3K9me2 deposition. Overall, these findings provide novel insights into the epigenetic regulation of adult muscle stem cells fate by lncRNAs.
- 12 January 2021
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 10
Open AccessEpigenetic regulation of Wnt7b expression by the cis-acting long noncoding RNA Lnc-Rewind in muscle stem cells
Skeletal muscle possesses an outstanding capacity to regenerate upon injury due to the adult muscle stem cell (MuSC) activity. This ability requires the proper balance between MuSC expansion and differentiation, which is critical for muscle homeostasis and contributes, if deregulated, to muscle diseases. Here, we functionally characterize a novel chromatin-associated long noncoding RNA (lncRNA), Lnc-Rewind, which is expressed in murine MuSCs and conserved in human. We find that, in mouse, Lnc-Rewind acts as an epigenetic regulator of MuSC proliferation and expansion by influencing the expression of skeletal muscle genes and several components of the WNT (Wingless-INT) signalling pathway. Among them, we identified the nearby Wnt7b gene as a direct Lnc-Rewind target. We show that Lnc-Rewind interacts with the G9a histone lysine methyltransferase and mediates the in cis repression of Wnt7b by H3K9me2 deposition. Overall, these findings provide novel insights into the epigenetic regulation of adult muscle stem cells fate by lncRNAs.